Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents
K Kelly, R Swords, D Mahalingam… - Leukemia & lymphoma, 2010 - Taylor & Francis
Imatinib is broadly used in the frontline treatment of chronic myeloid leukemia (CML).
Although long-term safety and efficacy have been established, some patients will not …
Although long-term safety and efficacy have been established, some patients will not …
Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents
K Kelly, R Swords, D Mahalingam… - Leukemia & …, 2010 - scholarship.miami.edu
Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase:
comparative safety profiles of newer agents - University of Miami Logo image Menu …
comparative safety profiles of newer agents - University of Miami Logo image Menu …
Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents.
K Kelly, R Swords, D Mahalingam… - Leukemia & …, 2010 - search.ebscohost.com
Imatinib is broadly used in the frontline treatment of chronic myeloid leukemia (CML).
Although long-term safety and efficacy have been established, some patients will not …
Although long-term safety and efficacy have been established, some patients will not …
Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents.
K Kelly, R Swords, D Mahalingam… - Leukemia & Lymphoma, 2010 - europepmc.org
Imatinib is broadly used in the frontline treatment of chronic myeloid leukemia (CML).
Although long-term safety and efficacy have been established, some patients will not …
Although long-term safety and efficacy have been established, some patients will not …
Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: Comparative safety profiles of newer agents
K Kelly, R Swords, D Mahalingam… - Leukemia and …, 2010 - scholars.northwestern.edu
Imatinib is broadly used in the frontline treatment of chronic myeloid leukemia (CML).
Although long-term safety and efficacy have been established, some patients will not …
Although long-term safety and efficacy have been established, some patients will not …
Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: Comparative safety profiles of newer agents
K Kelly, R Swords, D Mahalingam… - Leukemia and …, 2010 - ohsu.elsevierpure.com
Imatinib is broadly used in the frontline treatment of chronic myeloid leukemia (CML).
Although long-term safety and efficacy have been established, some patients will not …
Although long-term safety and efficacy have been established, some patients will not …
Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents
K Kelly, R Swords, D Mahalingam… - Leukemia & …, 2010 - pubmed.ncbi.nlm.nih.gov
Imatinib is broadly used in the frontline treatment of chronic myeloid leukemia (CML).
Although long-term safety and efficacy have been established, some patients will not …
Although long-term safety and efficacy have been established, some patients will not …